Impact of the time of initiation and line of biologic therapy on the retention rate of secukinumab in axial spondyloarthritis (axSpA): data from the French multicentre retrospective FORSYA study.
Maxime DougadosAudrey Lardy-CléaudEmilie DesfleursPascal ClaudepierrePhilippe GoupilleAdeline Ruyssen-WitrandAlain SarauxAnne TournadreDaniel WendlingCédric LukasPublished in: RMD open (2024)
The better secukinumab retention rate remotely from its launch is explained by its use at an earlier stage of the disease, suggesting a change in the behaviour of prescribing physicians. Our results emphasise the relevance of iterative evaluations of routine care treatments.
Keyphrases
- ankylosing spondylitis
- primary care
- rheumatoid arthritis
- healthcare
- cross sectional
- palliative care
- clinical trial
- study protocol
- stem cells
- randomized controlled trial
- big data
- magnetic resonance imaging
- emergency department
- bone marrow
- pain management
- affordable care act
- double blind
- chronic pain
- data analysis
- health insurance